CMS updates payment for certain COVID-19 lab tests
Over the next few weeks, members of the MedeAnalytics Product Consulting team will provide insight into the ways COVID-19 is changing the healthcare business landscape for payers and providers. Our Product Consulting team are true boots-on-the-ground experts; they interact daily with payers and providers on the frontlines of the coronavirus pandemic.
This gives each member of my team a unique, real-time perspective into the impact COVID-19 is having in healthcare right now.
The first post in this series is brought to us by Brenda Turner, who is director of Product Consulting. She takes a look at the Centers for Medicare & Medicaid Services (CMS) changes to payment schedules for COVID-19 lab tests and how they affect payers and providers.
In the meantime, please take a few minutes to find out how CMS has updated payments in response to COVID-19.
If your healthcare organization has any questions about how to solve the negative impacts on business caused by the coronavirus or about the ways analytics can help, please fill out the form below.
Please stay safe in these difficult times.
Andrea Sorensen, associate vice president, Product Consulting, MedeAnalytics
CMS updates payment for certain COVID-19 lab tests
By Brenda Turner
The COVID-19 landscape as it relates to testing is frequently changing as CMS made wholesale changes and smaller adjustments to payment schedules.
CMS announced Medicare will nearly double payment for certain lab tests that use high-throughput technologies to rapidly diagnose large numbers of 2019 Novel Coronavirus (COVID-19) cases.
Medicare will pay the higher payment of $100 for COVID-19 clinical diagnostic lab tests making use of high-throughput technologies developed by the private sector that allows for increased testing capacity, faster results, and more effective means of combating the spread of the virus. High-throughput lab tests can process more than 200 specimens a day using highly sophisticated equipment requiring specially-trained technicians and more time-intensive processes to ensure quality. Medicare will pay laboratories for the tests at $100 per test effective April 14, 2020, through the duration of the COVID-19 national emergency.
CMS and the US Departments of Labor and Treasury issued guidance to ensure Americans with private health insurance have coverage of COVID-19 diagnostic testing and certain other related services, including antibody testing, at no cost.
Specifically, the requirement for group health plans, and group and individual health insurance is to cover both diagnostic testing, and certain related items and services provided during a medical visit with no cost-sharing. This includes urgent care visits, emergency department visits, and in-person or telehealth visits to the doctor’s office that result in an order for or administration of a COVID-19 test.
Covered tests include all FDA-authorized COVID-19 diagnostic tests, COVID-19 diagnostic tests that developers request authorization for on an emergency basis, and COVID-19 diagnostic tests developed in and authorized by states. It also ensures that COVID-19 antibody testing also will be covered.
The initial pricing for the new codes U0001 and U0002 for the Centers for Disease Control and Prevention (CDC) test will be approximately $36 and non-CDC tests will initially be approximately $51. These prices may vary slightly depending on the local Medicare Administrative Contractor (MAC).
National, Private Insurers Pay for COVID-19 Testing
In March, several national insurers committed to paying for diagnostic testing for COVID-19 without cost-sharing, like copays and coinsurance, and many have since said they’ll waive cost-sharing for inpatient treatment as well. The April 11 guidance implements the Families First Coronavirus Response Act and the Coronavirus Aid, Relief and Economic Security Act, which requires private health plans and employer group health plans to cover COVID-19 testing with no out-of-pocket expenses.
The coverage requirement includes no cost-sharing for “certain related items and services” provided during a medical visit for COVID-19 testing. CMS said this means insurers must cover urgent care visits, emergency department visits and in-person or telehealth visits that result in an order for a COVID-19 test. Additionally, the guidance ensures coverage of COVID-19 antibody testing.
CMS said it sees the antibody test as a “key element in fighting the pandemic by providing a more accurate measure of how many people have been infected and potentially enabling Americans to get back to work more quickly.”
Additional information about these updates and other COVID-19 details can be found at:
- https://www.cms.gov/files/document/cms-2020-01-r.pdf
- https://www.cms.gov/files/document/mac-covid-19-test-pricing.pdf
- https://www.cms.gov/newsroom/press-releases/cms-increases-medicare-payment-high-production-coronavirus-lab-tests-0
- https://www.cms.gov/files/document/covid-ma-and-part-d.pdf
- https://www.cms.gov/files/document/FFCRA-Part-42-FAQs.pdf
- https://www.beckershospitalreview.com/payer-issues/5-insurers-waiving-costs-for-covid-19-treatment.html
Get our take on industry trends
How to help employer groups plan in a time of uncertainty
Employers and their sponsored health plans are thinking about next year’s benefit designs with a significant challenge not seen before: the effect of the coronavirus pandemic. There are important considerations to take into account before making any decisions about new or existing coverage. Becky Niehus, a director of Product Consulting at MedeAnalytics, explores these new issues and what employers can do to ensure employees are “covered.”
Read on...
Healthcare’s return to “normal” after COVID-19: Is it possible?
As providers determine how to get patients to return to facilities for routine disease management and preventive screenings, opportunities are ripe for the application of analytics to triage at the right time to the right setting. Data related to COVID-19 will continue to flow rapidly, but there are possibly more questions than answers now about a return to “normal.”
Read on...
Avoid COVID-19 modeling pitfalls by eliminating bias, using good data
COVID-19 models are being used every day to predict the course and short- and long-term impacts of the pandemic. And we’ll be using these COVID-19 models for months to come.
Read on...
Population Health Amid the Coronavirus Outbreak
In speaking with many colleagues throughout the provider and payer healthcare community, I’ve found an overwhelming sense of helplessness to the outbreak’s onslaught. This is exacerbated by the constant evolution of reported underlying medical conditions that indicate a higher risk of hospitalization or mortality for a coronavirus patient.
Read on...